Abstracts Archive - Page 1587 of 2607 - ACR Meeting Abstracts

Abstract Number: 2997 • 2017 ACR/ARHP Annual Meeting
Patient and Family Reported Psychosocial Areas of Concern within Pediatric Rheumatology: Quality Improvement Data and Implications for Practice
Nicole Tennermann and Melissa Hazen, Rheumatology, Boston Children's Hospital, Boston, MA
Background/Purpose: Psychosocial factors greatly impact the subjective disease experience and outcomes of children with rheumatic conditions. Attention to the psychosocial aspects of patients’ needs is…
Abstract Number: 135 • 2017 Pediatric Rheumatology Symposium
Epigenetic Profiling Of Juvenile Idiopathic Arthritis (JIA) Synovial Fluid Monocytes Points Towards a Role For Monocytes In Bone Damage
Janneke Peeters¹, Arjan Boltjes^2,3, Stephin Vervoort⁴, Paul Coffer¹, Bas Vastert^2,5, Femke van Wijk^2,3, Michal Mokry³, Teun de Vries^6,7 and Jorg van Loosdregt³, ¹Center for Molecular Medicine and Regenerative Medicine Center Utrecht, University Medical Center Utrecht, Utrecht, Netherlands, ²Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Division of Pediatrics, University Medical Center Utrecht, Utrecht, Netherlands, ⁴Peter MacCallum Cancer Centre, Melbourne, Australia, ⁵Division of Pediatric Rheumatology, University Medical Center Utrecht, Utrecht, Netherlands, ⁶Department of Oral Cell Biology and Functional Anatomy, Academic Centre for Dentistry Amsterdam, Amsterdam, Netherlands, ⁷Department of Periodontology, Academic Centre for Dentistry Amsterdam, Amsterdam, Netherlands
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is a multifactorial autoimmune disease characterized by the accumulation of various immune cells, including monocytes, in the joint synovial fluid…
Abstract Number: 49 • 2017 Pediatric Rheumatology Symposium
Perceptions of Methotrexate Intolerance in School-aged Children With Juvenile Idiopathic Arthritis
Charlene Hopper¹, Sarah Khan², Jacqueline Mancini² and Janet Rennick^3,4, ¹Rheumatology, Montreal Children's Hospital McGill University Health Centre, Montreal, QC, Canada, ²Ingram School of Nursing, McGill University, Montreal, QC, Canada, ³Nursing, Montreal Children's Hospital McGill University Health Centre, Montreal, QC, Canada, ⁴Ingram School of Nursing and Department of Pediatrics, McGill University, Montreal, QC, Canada
Background/Purpose: Methotrexate (MTX) remains an effective and commonly used disease modifying anti-rheumatic drug (DMARD) for the treatment of Juvenile Idiopathic Arthritis (JIA). Approximately half of the children taking MTX will…
Abstract Number: 11 • 2017 Pediatric Rheumatology Symposium
Safety of Adalimumab ± Methotrexate for the Treatment of Polyarticular Juvenile Idiopathic Arthritis (pJIA): STRIVE Registry
Hermine Brunner¹, Nicolino Ruperto², Kabita Nanda³, Mary Toth⁴, Ivan Foeldvari⁵, John F. Bohnsack⁶, Diana Milojevic⁷, C. Egla Rabinovich⁸, Daniel Kingsbury⁹, Katherine Marzan¹⁰, Pierre Quartier¹¹, Kirsten Minden¹², Elizabeth Chalom¹³, Gerd Horneff¹⁴, Rolf M. Kuester¹⁵, Jason A Dare¹⁶, Mareike Bereswill¹⁷, Jasmina Kalabic¹⁷, Hartmut Kupper¹⁸, Daniel J. Lovell¹⁹ and Alberto Martini², ¹Rheumatology, PRCSG, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²PRINTO-IRCCS Gaslini, Genova, Italy, ³Seattle Childrens Hospital, Bayside, NY, ⁴Rheumatology, Akron Children's Hospital, Akron, OH, ⁵Kinder- und Jugenrheumatologie, Hamburger Zentrum Kinder-und Jugendrheumatologie, Hamburg, Germany, ⁶Division of Allergy, Immunology and Pediatric Rheumatology, University of Utah, Salt Lake City, UT, ⁷Tufts Medical Center, Boston, MA, ⁸Duke University Medical Center, Durham, NJ, ⁹Pediatric Rheumatology, Randall Children's Hospital at Legacy Emanuel, Portland, OR, ¹⁰Children's Hospital Los Angeles, Los Angeles, CA, ¹¹Hopital Necker-Enfants Malades, Paris, France, ¹²Kinderklinik der Charite, Otto-Heubner Centrum, Berlin, Germany, ¹³PRCSG, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁴Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ¹⁵Orthopädiezentrum Altona, Hamburg, Germany, ¹⁶Arkansas Children’s Hospital, Little Rock, AR, ¹⁷AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ¹⁸Clinical Oncology/Immunology, AbbVie Deutschland GmbH & Co. KG, Ludnigshafen, Germany, ¹⁹Rheumatology MLC 4010, PRCSG, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: JIA is the most common chronic inflammatory rheumatic disease of childhood. Due to their known safety and efficacy, TNF inhibitors are used for long-term…
Abstract Number: 56 • 2017 Pediatric Rheumatology Symposium
Prevalence of Serum 14-3-3η in Juvenile Idiopathic Arthritis
Iris Reyhan¹, Olga S. Zhukov², Robert J. Lagier³, Robert Bridgforth⁴, Gary J Williams⁵, Joanna M. Popov², Stanley J. Naides² and Andreas Reiff⁶, ¹Rheumatology, Children's Hospital of Los Angeles, Los Angeles, CA, ²Immunology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, ³Research Support, Alameda, Quest Diagnostics Alameda, Alameda, CA, ⁴quest diagnostics Nichols Institue, clemente, CA, ⁵Nicolas Institue, Quest Diagnostics, San Juan Capistrano, CA, ⁶Childrens Hospital of Los Angeles, Los Angeles, CA
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common pediatric rheumatic disease. Currently, diagnosis is based on clinical assessment defined by the International League of…
Abstract Number: 30 • 2017 Pediatric Rheumatology Symposium
Cross-sectional Analysis of Depression and Medication Non-Adherence in Childhood-onset Systemic Lupus Erythematosus
Alaina M. Davis¹, T. Brent Graham¹, Yuwei Zhu² and Melissa L. McPheeters³, ¹Pediatric Rheumatology, Monroe Carell Junior Children's Hospital at Vanderbilt, Division of Pediatric Rheumatology, Nashville, TN, ²Biostatistics, Vanderbilt University, Department of Biostatistics, Nashville, TN, ³Health Policy, Vanderbilt University Medical Center, Department of Health Policy, Nashville, TN
Background/Purpose: The objectives of this study were to estimate prevalence of depression and medication non-adherence, describe demographic and disease characteristics associated with depression and medication…
Abstract Number: 129 • 2017 Pediatric Rheumatology Symposium
Cell-bound Complement Activation Products Correlate with Disease Activity in Childhood-onset Systemic Lupus Erythematosus
Joyce Hui-Yuen¹, Derren Barken², John Conklin³, Tyler O'Malley⁴, Andrew Eichenfield⁵, Amy Starr⁶, Lisa F. Imundo⁷, Thierry Dervieux⁴ and Anca Askanase⁸, ¹Cohen Children's Medical Center of New York, Lake Success, NY, ²Exagen Diagnostics, Vista, CA, ³1261 Liberty Way Suite C, Exagen Diagnostics, Vista, CA, ⁴Research and Development, Exagen Diagnostics, Vista, CA, ⁵Columbia University Medical Center, New York, NY, ⁶Pediatric Rheumatology, Columbia University Medical Center, New York, NY, ⁷Pediatrics, Columbia University Medical Center, New York, NY, ⁸Rheumatology, Columbia University Medical Center, New York, NY
Background/Purpose: Elevated levels of cell-bound complement activation products (C4d deposition on erythrocytes [EC4d] and B lymphocytes [BC4d], CB-CAPs) have been demonstrated to be sensitive and…
Abstract Number: 63 • 2017 Pediatric Rheumatology Symposium
Performance of Disease Activity Measures in Pediatric Patients With Enthesitis-related Arthritis
Rubén Burgos-Vargas¹, Gerd Horneff², Shirley M.L. Tse³, Pierre Quartier⁴, Kristina Unnebrink⁵ and Jaclyn K. Anderson⁶, ¹Hospital General de Mexico, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico, ²Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ³The Hospital for Sick Children, Toronto, ON, Canada, ⁴Hopital Necker-Enfants Malades, Paris, France, ⁵AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ⁶AbbVie Inc., North Chicago, IL
Background/Purpose: Enthesitis-related arthritis (ERA) is a category of juvenile idiopathic arthritis (JIA), with clinical features similar to those of adult spondyloarthritis (SpA). An unmet ERA…
Abstract Number: 82 • 2017 Pediatric Rheumatology Symposium
Disease Burden and Social Impact of Chronic Nonbacterial Osteomyelitis on Affected Children and Young Adults
Melissa Oliver¹, Tzielan Lee², Bonnie Halpern-Felsher³, Elizabeth Murray⁴, Rebecca Gholson⁵ and Yongdong Zhao⁶, ¹Pediatric Rheumatology, Stanford University, Department of Pediatric Rheumatology, Palo Alto, CA, ²Stanford University, Department of Pediatric Rheumatology, Palo Alto, CA, ³Pediatrics, Adolescent Medicine, Stanford University, Department of Pediatrics, Adolescent Medicine, Palo Alto, CA, ⁴CRMO Facebook Support Group, Seattle, WA, ⁵CRMO Facebook Support Group, Asheville, NC, ⁶Seattle Children's Hospital, Department of Pediatric Rheumatology, University of Washington, Seattle, WA
Background/Purpose: Chronic Nonbacterial Osteomyelitis (CNO) is a rare autoinflammatory bone disorder that can result in bone destruction, persistent bone pain, growth disturbances and pathological fractures.…
Abstract Number: 110 • 2017 Pediatric Rheumatology Symposium
Risk Factors for Poor Health-Related Quality of Life in Children with Inflammatory Brain Diseases
Elina Liu¹, Anastasia Dropol², Marinka Twilt², Pascal Tyrrell³, Shehla Sheikh⁴, Susanne Benseler² and The BrainWorks Investigator Network, ¹Pediatric Rheumatology, Alberta Children's Hospital, Calgary, AB, Canada, ²Pediatric Rheumatology, University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada, ³Medical Imaging, University of Toronto, Toronto, ON, Canada, ⁴Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Inflammatory Brain diseases (IBrainD) are increasingly recognized causes of devastating neurological deficits in previously healthy children. Although the mortality has dramatically improved, disease and…
Abstract Number: 33 • 2017 Pediatric Rheumatology Symposium
An extracellular ionic milieu renders human granulocytic S100A12 into a pro-inflammatory TLR4-binding alarmin
Christoph Kessel¹, Sabrina Fuehner¹, Bastian Zimmermann², Dirk Holzinger¹, Helmut Wittkowski¹, Claas Hinze¹ and Dirk Foell¹, ¹Department of Pediatric Rheumatology and Immunology, University of Muenster, Muenster, Germany, ²Biaffin GmbH & Co KG, Kassel, Germany
Background/Purpose: Granulocytic S100A12 is a member of the calgranulin-subgroup within the S100 family of calcium-binding proteins. Similar to other S100 proteins S100A12 can bind divalent…
Abstract Number: 131 • 2017 Pediatric Rheumatology Symposium
Balancing JAK/STAT-signaling with tofacitinib may foster anti-inflammatory functions of human monocytes
Friederike Cordes¹, Eva Lenker², Toni Weinhage², Georg Varga² and Dirk Foell³, ¹Gastroenterology, Internal Medicine, University of Muenster, Muenster, Germany, ²Department of Pediatric Rheumatology and Immunology, University of Muenster, Muenster, Germany, ³Pediatric Rheumatology and Immunology, University of Muenster, Muenster, Germany
Background/Purpose: Monocytes are bridging natural and acquired immunity. Information about JAK signaling in monocytes is scarce especially in an inflammatory milieu. JAK-inhibition is a promising…
Abstract Number: 71 • 2017 Pediatric Rheumatology Symposium
Consensus-based diagnostic approach to systemic juvenile idiopathic arthritis in Germany
Claas Hinze¹, Dirk Holzinger¹, Elke Lainka², Johannes Peter Haas³, Tilmann Kallinich⁴, Ulrich Neudorf², Helmut Wittkowski¹, Gerd Horneff⁵, Dirk Foell⁶ and PRO-KIND study group on SJIA, ¹Department of Pediatric Rheumatology and Immunology, University of Muenster, Muenster, Germany, ²University of Essen, Essen, Germany, ³Center for Pediatric and Adolescent Rheumatology Garmisch-Partenkirchen, Garmisch-Partenkirchen, Germany, ⁴Charite, University Medicine Berlin, Berlin, Germany, ⁵Asklepios Klinik Sankt Augustin GmbH, Sankt Augustin, Germany, ⁶Pediatric Rheumatology and Immunology, University of Muenster, Muenster, Germany
Background/Purpose: Systemic juvenile idiopathic arthritis (SJIA) is currently classified by the International League of Associations for Rheumatology (ILAR) classification criteria. It is characterized by severe…
Abstract Number: 98 • 2017 Pediatric Rheumatology Symposium
Contraceptive use, Counseling given and the Occurrence of Venous Thrombus Embolism in Adolescent Systemic Lupus Erythematosus
Martha Curry¹, Jennifer Kurkowski², Jane Geyer³, Julie Hakim³, Haleh Sangi⁴ and Marietta deGuzman⁵, ¹Pediatric Immunology, Allergy and Rheumatology, Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine, Division Pediatric and Adolescent Gynecology, Houston, TX, ³Baylor College of Medicine, Division of Pediatric and Adolescent Gynecology, Houston, TX, ⁴Baylor College of Medicnine,Division of Pediatric and Adolescent Gynecology, Houston, TX, ⁵Baylor College of Medicine, Division of Pediatric Rheumatology, Houston, TX
Background/Purpose: According to the Center for Disease Control, 46.8% of high school students surveyed in 2013 have been sexually active. Of those surveyed 34% had…
Abstract Number: 42 • 2017 Pediatric Rheumatology Symposium
Evaluation of a Dosing Regimen for Tocilizumab in Patients Younger Than Two Years of Age With Systemic Juvenile Idiopathic Arthritis
Navita L. Mallalieu¹, Joy Hsu¹, Karen Wang¹, Sunethra Wimalasundera², Chris Wells², Inmaculada Calvo Penades³, Rubén J. Cuttica⁴, Hans-Iko Huppertz⁵, Rik Joos⁶, Yukiko Kimura⁷, Diana Milojevic⁸, Margalit Rosenkranz⁹, Kenneth Schikler¹⁰, Tamas Constantin¹¹ and Carine Wouters¹², ¹Roche Innovation Center, New York, NY, ²Roche Products Ltd., Welwyn Garden City, United Kingdom, ³Hospital Universitario y Polytécnico La Fe, Valencia, Spain, ⁴Hospital General de Niños Pedro de Elizalde, Buenes Aires, Argentina, ⁵Professor Hess Children's Hospital, Bremen, Germany, ⁶ZNA Jan Palfijn Antwerpen, Antwerp, Belgium, ⁷Hackensack University Medical Center, Hackensack, NJ, ⁸Tufts Medical Center, Boston, MA, ⁹Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ¹⁰University of Louisville Hospital, Louisville, KY, ¹¹Semmelweis University, Budapest, Hungary, ¹²University Hospital Gasthuisberg, Leuven, Belgium
Background/Purpose: Tocilizumab (TCZ) is approved for the treatment of systemic juvenile idiopathic arthritis (sJIA) based on clinical trials in patients ≥2 years of age. This…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].